Figure 1

SIRT7 amplification and over-expression is associated with metastatic disease and poor prognosis.

(A), Analysis of several cBio Cancer Genomics datasets shows that SIRT7 is amplified in many epithelial cancers and in mesenchymal sarcomas. (B), Analysis of a reported mutational landscape of metastatic prostate cancer shows exclusive amplification of SIRT7 in prostate cancer patients with metastatic disease and poor survival¹². (C), Meta-analysis of the prostate cancer dataset¹³ using the Oncomine database showing significantly higher expression of SIRT7 in metastatic tumor sites compared to primary tumor or normal prostate tissues. (D), SIRT7 expression in prostate cancer patient tissues versus normal prostate controls. (E), SIRT7 expression in primary prostate cancer tumors versus metastatic tumor tissue. In (D) and (E), levels are log2 normalized values (median, lower and upper quartiles are shown), retrieved from Lapointe et al¹⁴.